Quick Answer
Prelude Therapeutics Inc reported Net Income of -$99.50 million for fiscal year 2025.
Prelude Therapeutics Inc Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$99.50M | +21.8% |
| 2024 | -$127.17M | -4.4% |
| 2023 | -$121.83M | -5.5% |
| 2022 | -$115.44M | -3.4% |
| 2021 | -$111.69M | -96.2% |
| 2020 | -$56.93M | -106.5% |
| 2019 | -$27.57M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$19.73M | +38.9% | +36.8% |
| June 30, 2025 | -$31.23M | +10.1% | +2.7% |
| March 31, 2025 | -$32.09M | -2.1% | +0.6% |
| September 30, 2024 | -$32.27M | -5.4% | +7.1% |
| June 30, 2024 | -$34.74M | -14.2% | -10.5% |
| March 31, 2024 | -$31.43M | -13.4% | -2.7% |
| September 30, 2023 | -$30.61M | -2.2% | -0.6% |
| June 30, 2023 | -$30.43M | -11.2% | -9.8% |
- Prelude Therapeutics Inc showed an increase of +21.8% in Net Income compared to the prior fiscal year.
- Over the 2019–2025 period, Prelude Therapeutics Inc’s net income has declined by 260.9% (from -$27.57 million to -$99.50 million).
- The most recent figure is from Prelude Therapeutics Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: